GI Cancers | Clinical

July 16, 2021

The heterogeneity of tumors in gastrointestinal cancers continues to pose a challenge, according to Wells Messersmith, MD.

July 12, 2021

Although the genetic makeup of biliary tract cancer is rich, only recently has the field been able to show the benefit of treating patients with effective targeted agents, in the advanced setting.

July 07, 2021

ALX148, a CD47 inhibitor in combination with chemotherapy and trastuzumab is a safe and well-tolerated treatment for patients with second-line or greater HER2-positive gastroesophageal junction cancer.

July 06, 2021

Pembrolizumab has been voluntarily withdrawn from the North American market as a treatment option for patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

July 03, 2021

The combination regimen was well tolerated with promising preliminary anti-tumor activity in patients with heavily pretreated esophageal cancer, who had not received immunotherapy.

July 02, 2021

The combination of paclitaxel and GSK2636771 showed encouraging antitumor activity and a manageable toxicity profile and in patients with PTEN-deficient advanced gastric cancer who progressed after first line chemotherapy.

July 02, 2021

Final overall survival and long-term safety results of the phase 3 NETTER-1 trial were presented during the World Congress on Gastrointestinal Cancer 2021.

July 01, 2021

Treatment with avapritinib in Chinese patients with PDGFRA D842V-mutant gastrointestinal stromal tumors revealed promising clinical benefit, according to a bridging study of the NAVIGATOR trial.

July 01, 2021

Pembrolizumab monotherapy demonstrated improvement in health-related quality of life in patients with previously treated metastatic microsatellite instability-high/ mismatch repair deficient advanced noncolorectal solid tumors, with the biggest improvements seen in those who achieved a complete remission or partial remission.

July 01, 2021

Dostarlimab achieved durable antitumor responses in patients with non-endometrial mismatch repair–deficient solid tumors treated in an expansion cohort of the phase 1 GARNET trial, according to interim findings presented during the ESMO World Congress on Gastrointestinal Cancer.